December 16, 2024
Invex Therapeutics (ASX:IXC) finds new promise for alzheimer’s treatment with exenatide in 3D brain model
Invex Therapeutics (ASX:IXC) has demonstrated Exenatide’s ability to improve neuronal cell survival by up to 45% in a 3D Alzheimer’s Disease brain model, marking a promising step in neurodegenerative research.